Emerging respiratory viruses: challenges and vaccine strategies
about
Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particleCross-Species Virus Transmission and the Emergence of New Epidemic DiseasesEmerging Infections of CNS: Avian Influenza A Virus, Rift Valley Fever Virus and Human ParechovirusDevelopment of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production.Avian influenza virus (H5N1): a threat to human health.Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutininVesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses.New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice.Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades.Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fab-phage display library.Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.Extensive multiplex PCR diagnostics reveal new insights into the epidemiology of viral respiratory infections.Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines.Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge.Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particlesMicroneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice.A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferretsIdentification of sequence mutations affecting hemagglutinin specificity to sialic acid receptor in influenza A virus subtypes.A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection.Complex patterns of human antisera reactivity to novel 2009 H1N1 and historical H1N1 influenza strains.Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza.A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques.New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus.Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities.Pneumonia research to reduce childhood mortality in the developing world.A novel M2e-multiple antigenic peptide providing heterologous protection in mice.Detection of respiratory viruses by molecular methodsInfluence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age.Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccinationMolecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination.Advances in the diagnosis of respiratory tract infections: role of the Luminex xTAG respiratory viral panel.Animal models in virus research: their utility and limitations.Interleukin-15 is critical in the pathogenesis of influenza a virus-induced acute lung injury.Proposed lead molecules against Hemagglutinin of avian influenza virus (H5N1).Evaluation of a multiplexed PCR assay for detection of respiratory viral pathogens in a public health laboratory setting.Efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the classical swine H1N1 subtype influenza virus in mice and pigs.Structural and antigenic stability of H5N1 hemagglutinin trimer upon release from polyanhydride nanoparticles.
P2860
Q21562299-005A6312-200E-4FD8-BFAC-0A00ECA83B95Q27486915-72F7EF6D-1623-47A9-A973-2A6D4BC519EFQ28085230-0C8217F1-E41C-4399-A48D-9184B06CA522Q30227434-821A770A-A6BB-4137-8ABD-D07DCF9AAA10Q30361041-4C373CF3-69CF-4C04-81C6-A37ADB6B6B2AQ30361736-5AC5D3B7-50D7-43A1-8C7C-CD24ECBB11CBQ30361939-0FD8C792-381F-440E-9612-F9FD8474536EQ30362760-8D85F7F9-2347-45E5-9E81-A75C47C7DC37Q30365380-255A84A6-7B09-4837-9855-A7072DBFE30CQ30371649-C5497679-E986-4F37-B828-E3A053BA6779Q30372987-2B328909-3BE2-41E4-9956-0E04581B78B0Q30382097-B98099AD-C395-4173-9578-B04D3A075A84Q30384878-78B60290-493E-44D5-AEDE-DE555B4F29FEQ30385120-ECD7F2A9-CD31-40BF-9090-180A2A6AFFE3Q30385271-656C769A-23A3-499A-990C-5018B36F7724Q30385999-422731F3-0762-4DBD-99F5-FC8BBB10A477Q30390753-5627EDEA-DD52-4021-AE4F-D70009B4A748Q30391402-CE390546-FFB2-4194-A05A-6B3B08CD365FQ30399675-AFDD3977-E726-47D2-B39B-72E09FF4D1FEQ30400302-476C137B-3A8D-4215-8496-CD94005544FAQ30414652-93E24416-8545-4142-AA9D-35055240B180Q30419472-6C3418F0-9048-494D-B86E-49FB19E57947Q30424161-2E314018-442B-4906-AC29-5993D7AF48CEQ33474344-373AA44C-4347-40B3-81E6-B0FF1DE0C4F7Q35076920-B905C0B3-0E42-46F8-88AD-1AC50779301BQ35078213-D9C6F1FD-6EBE-476E-BD71-D19E40829D32Q35965224-1BD7F240-FCC7-4FF5-BA26-DDE364DA556CQ36513346-64A91D3C-5C18-4AC1-9072-5099BFDBC988Q36731466-A0558467-A952-4EA7-9F3C-8E3005D97485Q36943130-419F99B6-9FDE-47F3-912A-05E356393FCFQ36977899-D2E80DB7-33A1-4C88-A563-F44BFF931F6DQ37157157-26209DCE-37B7-4580-A307-8CDA14F97A42Q37635478-B622943F-A576-4456-9867-522755C61C2EQ37857325-3A172097-2720-462E-9C1E-8B2D5BD49FC8Q38043556-E39B19AC-266B-4D31-A3C5-DF705AA67B3AQ40756519-E016849C-485E-4646-AEE5-EB36A3A0B751Q42060560-590269FA-EB57-4E6C-8793-2C2B60397F65Q42175889-158CA1A3-4FF0-4BE5-9913-64413AE55AF3Q42209282-F20CF6AE-DD08-4031-AE1B-EE1F9F3212D2Q42242342-6D3249AB-4211-4988-A799-32783F444E25
P2860
Emerging respiratory viruses: challenges and vaccine strategies
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Emerging respiratory viruses: challenges and vaccine strategies
@ast
Emerging respiratory viruses: challenges and vaccine strategies
@en
type
label
Emerging respiratory viruses: challenges and vaccine strategies
@ast
Emerging respiratory viruses: challenges and vaccine strategies
@en
prefLabel
Emerging respiratory viruses: challenges and vaccine strategies
@ast
Emerging respiratory viruses: challenges and vaccine strategies
@en
P2860
P356
P1476
Emerging respiratory viruses: challenges and vaccine strategies
@en
P2093
Laura Gillim-Ross
P2860
P304
P356
10.1128/CMR.00005-06
P407
P577
2006-10-01T00:00:00Z